This interview is the second of a 2-part series with Dr. Randall Bateman about Alzheimer’s disease clinical trials participation.
Dr. Bateman is a neurologist and Alzheimer’s researcher at Washington University in St. Louis and Director of DIAN and DIAN-TU.
In this conversation, we discuss how data and samples from the DIAN and DIAN-TU studies accelerate progress worldwide, the importance of continued study participation, brain donation, new tau-targeting drug trials, and more.
If you haven’t already seen it, be sure to watch Part 1 of this 2-part interview, which covers Basics of Alzheimer’s Research.
And don’t forget about our Guide to Participating in User Research.
About Dr. Randall Bateman
Dr. Randall Bateman is a neurologist and Alzheimer’s researcher at Washington University in St. Louis. His lab (Bateman Lab) developed key tools that allow researchers to detect Alzheimer’s pathology—like amyloid plaques and tau tangles—in people who are still cognitively normal.
He also leads the Dominantly Inherited Alzheimer’s Network (DIAN) and the DIAN-TU trials (Therapeutic Unit), a groundbreaking set of studies specifically focused on FAD. These research efforts include:
Global observational studies that monitor FAD families over time
Clinical trials testing treatments that aim to prevent or delay Alzheimer’s in people who carry a FAD mutation
Dr. Bateman works closely with families to make sure their participation is meaningful, respectful, and scientifically vital.